Guideline concordance in triple‐negative breast cancer: What does it measure?
Cancer · 01.04.2026 · 132 (7)
DOI: 10.1002/cncr.70381 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer, online erschienen am 29.03.2026. Verfasst von Jennifer L Caswell-Jin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, California, USA. Die Arbeit nennt 11 Literaturangaben. Gefördert von: Stanford Cancer Institute Innovation Award.
Abstract (Originalsprache)
Guideline‐concordant care in triple‐negative breast cancer was associated with improved survival, including from nonbreast cancer causes. This editorial explores what broader patient and health system influences, beyond treatment, are captured by guideline concordance.
Autor:innen und Institutionen
- Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, California, USA.
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA.
ORCID-Profile: Jennifer L Caswell-Jin, Allison W Kurian
Förderung
- Stanford Cancer Institute Innovation Award
Zitieren
APA
Caswell-Jin, J. L., Dickerson, J. C., & Kurian, A. W. (2026). Guideline concordance in triple‐negative breast cancer: What does it measure?. Cancer, 132(7). https://doi.org/10.1002/cncr.70381
Vancouver
Caswell-Jin JL, Dickerson JC, Kurian AW. Guideline concordance in triple‐negative breast cancer: What does it measure?. Cancer. 2026;132(7). doi:10.1002/cncr.70381
BibTeX
@article{CaswellJin2026,
author = {Caswell-Jin, Jennifer L and Dickerson, James C and Kurian, Allison W},
title = {Guideline concordance in triple‐negative breast cancer: What does it measure?},
journal = {Cancer},
year = {2026},
volume = {132},
number = {7},
doi = {10.1002/cncr.70381}
}
EUVIMED